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RatsAbstract The current study was designed to investigate the possible protective effect of omega-3
fatty acids from fish oil on hepatic fibrosis induced by thioacetamide (TAA) in male rats. The exper-
imental animals were divided into four groups. The first group was received saline solution and
served as control. The second group was given 250 mg/kg body weight of TAA. The third group
was treated with omega-3 fatty acids and TAA. The fourth group was given saline solution and sup-
plemented with omega-3 fatty acids. Treatment of rats with TAA for three and six weeks resulted in
a significant decrease in body weight gain, while the value of liver/body weight ratio was statistically
increased. Furthermore, the levels of serum alanine aminotransferase, aspartate aminotransferase,
alkaline phosphatase, gamma glutamyl transferase and total bilirubin were significantly increased.
After three weeks of exposure to only TAA, liver sections showed an abnormal morphology char-
acterized by noticeable fibrosis with the extracellular matrix collagen contents and damage of liver
cells’ structure. Liver sections from rats treated with only TAA for six weeks revealed an obvious
increase in extracellular matrix collagen content and bridging fibrosis. Treating TAA-intoxicated
rats with omega-3 fatty acids significantly attenuated the severe physiological and histopathological
changes. Finally, the present investigation suggests that omega-3 fatty acids could act against hep-
atic fibrosis induced by TAA due to its antioxidant properties, thus supporting its use in hepatic
fibrosis therapy.
 2016 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatic fibrosis is a dynamic wound-healing response to
chronic hepatic injuries. Without effective treatments, reversi-
ble liver fibrosis at an early stage leads to irreversible cirrhosis.
Chronic liver injury leads to a progressive wound healing
response that eventually results in liver fibrosis characterized
by both quantity and quality alterations of hepatic extracellu-
lar matrix, ECM, (Liu et al., 2006). Moreover, liver fibrosis
represents the response of the liver to diverse chronic insults
such as parasitic disease, chronic viral infection (hepatitis Bin male
2 A.M. Al-Attar, H.A. Al-Retheaand C), immunologic attack (autoimmune hepatitis), heredi-
tary metal overload, toxic damage, etc. Because of the world-
wide prevalence of these insults, liver fibrosis is common and is
associated with significant morbidity and mortality (Chen
et al., 2002; Han, 2002; Shen et al., 2003).
Thioacetamide (TAA) is a chemical originally widely used
as a fungicide, a curing ingredient, a chemical reagent, a raw
medicine, a textile dye, and a finishing auxiliary (Chen et al.,
2006).
TAA is a model hepatotoxicant and responsible of severe
damage of the cells with significant toxic effects on the biosyn-
thesis of macromolecules including proteins and nucleic acids
(Yang et al., 1998). Furthermore, a different studies showed
that the exposure to TAA caused liver injury, fibrosis and cir-
rhosis in experimental animals (Al-Attar, 2011, 2012;
Abramovitch et al., 2015; Al-Attar and Shawush, 2015; Al-
Attar et al., 2015; Ali et al., 2015; Luo et al., 2015).
The medical management of liver diseases or disorders
including liver fibrosis is currently inadequate, so far no ther-
apy has successfully prevented the progression of hepatic dis-
ease. Even though newly developed drugs have been used to
treat chronic liver diseases, often these drugs have side effects.
It is therefore necessary to search for alternative drugs for the
treatment of liver diseases to replace currently used drugs of
doubtful efficacy and safety (Bruck et al., 1996; Dhiman
et al., 2012). Additionally, there is an increasing interest in
the alternative medicines for the treatment of liver diseases
and associated metabolic derailments which include herbal
remedies and dietary supplements (Handa et al., 1985;
Connor, 2000; Sharma and Shukla, 2010).
Dietary fats and oils are known as macronutrients which
provide concentrated source of energy for the metabolic pro-
cesses. In addition, fats are the main source of fat-soluble vita-
mins (Sanchez-Muniz and Bastida, 2006). Dietary fats are
composed of different types of fatty acids which are saturated,
monounsaturated and polyunsaturated. Evidence has been
shown that dietary fats can have important effects on human
health. Fish oil is most widely used as food supplements.
Owing to its wide array of biological actions public and scien-
tific interest has been directed toward the role of fish oil in
health promotion and disease prevention. Dietary fish oil,
which provides omega-3 fatty acids, has been shown to have
beneficial effects on some chronic degenerative diseases such
as cardiovascular disease (Car and Webel, 2012; Xin et al.,
2012), rheumatoid arthritis (Miles and Calder, 2012), diabetes,
other autoimmune diseases (Calder, 2007; Chapkin et al.,
2009), and cancer (Cockbain et al., 2012; Vaughan et al.,
2013). The beneficial effects of fish oil seem to be due to its
high content of the omega-3 polyunsaturated fatty acids
(PUFAs) such as docosahexaenoic acid (DHA) and eicosapen-
taenoic acid (EPA). Scientific evidence revealed that a diet rich
in long chain omega-3 fatty acids help in the development of
healthy brain, heart and immune system. It has a role in joint
movement, balanced mood, a sense of well being, strength, sta-
mina and maintaining cholesterol levels within the normal
range. Omega-3-fatty acids contain about 60% of long chain
omega-3 fatty acids DHA and EPA as combined. The most
widely available source of EPA and DHA is cold water oily
fish such as salmon, herring, mackerel, anchovies and sardines
(Bolles and Begg, 2000). In recent years, fish oil is gaining
attention as a nutraceutical and source of potential pharma-
ceuticals (Kaur et al., 2014). Therefore, the present studyPlease cite this article in press as: Al-Attar, A.M., Al-Rethea, H.A. Chemoprotective
rats. Saudi Journal of Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.201was conducted to investigate the effect of omega-3 fatty acids
from fish oil on hepatic fibrosis induced by TAA.
2. Materials and methods
2.1. Animals
Male albino rats of the Wistar strain (Rattus norvegicus),
weighing 94.2–134.6 g were used in the present study. The
experimental animals were obtained from the Experimental
Animal Unit of King Fahd Medical Research Center, King
Abdulaziz University, Jeddah, Saudi Arabia. Rats were accli-
matized to the laboratory conditions for one week prior to
the initiation of experimental treatments. The experimental
animals were housed in standard plastic cages and maintained
under controlled laboratory conditions of humidity (65%),
temperature (20 ± 1 C) and 12:12 h light: dark cycle. Rats
were fed ad libitum on normal commercial chow and had free
access to water. The experimental treatments were conducted
in accordance with ethical guidelines of the Animal Care and
Use Committee of King Abdulaziz University.
2.2. Experimental design
A total of sixty rats were randomly divided into four experi-
mental groups, fifteen rats each. The experimental groups were
treated as follows:
(1) Rats of group 1 were served as controls and intraperi-
toneally injected with saline solution (0.9% NaCl), twice
weekly.
(2) Rats of group 2 were given 250 mg/kg body weight of
TAA (Sigma–Aldrich Corp., St. Louis, MO, USA) by
intraperitoneal injection, twice weekly.
(3) Rats of group 3 were orally supplemented with omega-3
fatty acids from fish oil (Pharma Nord ApS, Denmark)
at a dose of 800 mg/kg body weight/day. Moreover, they
were intraperitoneally injected with TAA at the same
dose given to group 2.
(4) Rats of group 4 were intraperitoneally injected with sal-
ine solution (0.9% NaCl), twice weekly and were orally
supplemented with omega-3 fatty acids from fish oil at a
dose of 800 mg/kg body weight/day.
2.3. Body weight determinations
The body weights of rats were determined at the start of the
experimental period, after three and six weeks using a digital
balance. These weights were measured at the same time during
the morning (Al-Attar and Zari, 2010). Moreover, the experi-
mental animals were observed for signs of abnormalities
throughout the period of study.
2.4. Blood serum analyses
After three and six weeks, the experimental animals were
fasted for 12 h, water was not restricted, and then anaes-
thetized with diethyl ether. Blood samples were collected from
orbital venous plexus in non–heparinized tubes, centrifuged ateﬀect of omega-3 fatty acids on thioacetamide induced hepatic ﬁbrosis in male
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Figure 2 Changes of body weight after six weeks in control
(group 1), TAA (group 2), omega 3 plus TAA (group 3) and
omega 3 (group 4) treated rats.
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Figure 3 Changes of liver/body weight ratio at three weeks in
control, TAA, omega 3 plus TAA and omega 3 treated rats.
Chemoprotective effect of omega-3 fatty acids 32500 rpm for 15 min and blood sera were then collected and
stored at 80 C. Serum samples were used to determine the
levels of alanine aminotransferase (ALT), aspartate amino-
transferase (AST), alkaline phosphatase (ALP), gamma glu-
tamyl transferase (GGT) and total bilirubin. The levels of
serum ALT and AST were measured using the method of
Reitman and Frankel (1957). The methods of MacComb and
Bowers (1972), Szasz (1969), Doumas et al. (1973) were used
to estimate the levels of serum ALP, GGT and total bilirubin
respectively.
2.5. Weight changes of liver
After three and six weeks, livers were carefully excised and
weighed for the evaluation of their ratios/body weight. The
ratio was calculated by the following equation (Al-Attar,
2010):
Ratio ¼ Liver weight
Body weight
 100
2.6. Histopathological examinations
After blood sampling, rats were dissected and the livers were
preserved in 10% formalin immediately after removal from
the animals. Paraffin sections were stained with hematoxylin
and eosin, and Masson’s trichrome. Liver sections were exam-
ined microscopically and photographed.
2.7. Statistical analysis
The data were analyzed using the Statistical Package for Social
Sciences (SPSS for windows, version 22.0). Each value is
expressed as mean ± standard deviation (S.D.) and values
were analyzed using a two-way analysis of variance (ANOVA)
to determine differences between the mean values of experi-
mental groups. P-values of less than 0.05 were considered as
significant.
3. Results
The body weights after three weeks of all experimental groups
are represented in Fig. 1. A gradual increase in the body weight
gain of normal control rats and those supplemented with0
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Figure 1 Changes of body weight after three weeks in control
(group 1), TAA (group 2), omega 3 plus TAA (group 3) and
omega 3 (group 4) treated rats.
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75.4%, compared with their initial body weights. Significant
decreases in the values of body weight gain were observed in
rats treated with TAA and omega-3 plus TAA. The minimum
body weight gain was noted in TAA-intoxicated rats (52.7%)
followed by omega-3 plus TAA treated rats (66.7%). Fig. 2
demonstrates the body weights of all experimental groups after
six weeks. The maximum body weight gain was noted in nor-
mal control rats (181.4%). The minimum body weight gain0
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Figure 4 Changes of liver/body weight ratio at six weeks in
control, TAA, omega 3 plus TAA and omega 3 treated rats.
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4 A.M. Al-Attar, H.A. Al-Retheawas noted in TAA-intoxicated rats (106.7%) followed by
omega-3 plus TAA treated rats (124.1%). Supplementation
with omega-3 in normal rats showed a remarkable increase
in the percentage change of body weight (149.3%). After three
weeks, the values of liver/body weight ratio were statistically
increased in rats treated with TAA (10.6%) and omega-3 plus
TAA (21.3%) compared with control rats (Fig. 3). The values
of liver/body weight ratio were significantly elevated after six
weeks in rats exposed to TAA (40.5%) and omega-3 plus
TAA (21.4%) compared with control rats. Additionally, there
was no significant difference in the value of liver/body weight
ratio in normal rats supplemented with omega-3 (Fig. 4).0
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Figure 5 (A–E) The levels of ALT, (A) AST, (B) ALP, (C) GGT (D)
TAA and omega 3 treated rats for three weeks. *Indicates a signific
significant difference between rats treated with TAA and omega 3 plus T
treated with omega 3 plus TAA and omega 3.
Please cite this article in press as: Al-Attar, A.M., Al-Rethea, H.A. Chemoprotective
rats. Saudi Journal of Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.201The levels of serum ALT, AST, ALP, GGT and total biliru-
bin in control, TAA, omega-3 plus TAA and omega-3 treated
rats after three weeks are shown in Fig. 5(A–E). Statistical
increases in the level of serum ALT were observed in rats sub-
jected to TAA (1153.5%) and omega-3 plus TAA (167.5%)
compared with control rats. Notable increases in the level of
serum AST were observed in TAA (1058.1%) and omega 3
plus TAA treated rats (221.1%) as compared with control rats.
The levels of serum ALP were statistically elevated in rats trea-
ted with TAA (295.4%) and omega-3 plus TAA (73.2%) com-
pared with control rats. Serum GGT level was statistically
enhanced in rats exposed to TAA (951.8%) and omega-3 plus0
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Chemoprotective effect of omega-3 fatty acids 5TAA (158.4%) compared with control rats. TAA administra-
tion to normal rats significantly increased the level of serum
total bilirubin (1110.9%) compared with control rats. A statis-
tical increase in the level of serum total bilirubin was observed
in omega-3 plus TAA treated rats (249.4%) compared with
control rats. On the other hand, no statistically significant dif-
ference was observed in the level of serum ALT, AST, ALP,
GGT and total bilirubin in omega-3 treated rats.
The levels of serum ALT, AST, ALP, GGT and total biliru-
bin in control, TAA, omega-3 plus TAA and omega-3 treated
rats after six weeks are shown in Fig. 6(A–E). A highly signif-0
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Figure 6 (A–E) The levels of ALT, (A) AST, (B) ALP, (C) GGT (D)
TAA and omega 3 treated rats for six weeks. *Indicates a significa
significant difference between rats treated with TAA and omega 3 plus T
treated with omega 3 plus TAA and omega 3.
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rats. Saudi Journal of Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.201icant increase in the level of serum ALT was observed in rats
exposed to TAA (853.6%) compared with control and
omega-3 treated rats. Administration of omega-3 plus TAA
resulted in a marked increase (398.3%) in the level of serum
ALT compared with control rats. TAA administration to nor-
mal rats significantly elevated the level of serum AST (559.2%)
compared with control rats. The level of serum AST was sig-
nificantly increased in rats treated with omega-3 plus TAA
(312.7%). According to the data shown in Fig. 6C, significant
elevations in the level of serum ALP were noted in rats treated
with TAA (360.3%) and omega-3 plus TAA (174.8%)0
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6 A.M. Al-Attar, H.A. Al-Retheacompared with control rats. Relative to the control rats, the
experimental rats exposed to TAA exhibited a significant
increase in the level of serum GGT (467.1%). The level of
serum GGT was statistically enhanced in omega-3 plus TAA
treated rats (104.2%). As shown in Fig. 6E, a significant
enhancement in the level of serum total bilirubin was observed
in rats treated with TAA (891.6%) and omega-3 plus TAA
(188.2%) as compared with control rats. Treatment of rats
with omega-3 alone did not cause any significant change in
the levels of serum ALT, AST, ALP, GGT and total bilirubin.
As shown in Fig. 7A and F, the control and omega-3 trea-
ted groups, normal hepatic architecture with central vein and
radiating hepatic cords were seen. The liver sections of these
groups showed normal liver cells or hepatocytes with preserved
cytoplasm, prominent nucleus and nucleolus, and well brought
out central vein. These cells are cuboidal epithelial cells
arranged in anastomosing plates and cords. In classical lob-
ules, the plates radiate from the central vein and cords alter-
nate with sinusoids. After three weeks of exposure to TAA,
liver sections showed an abnormal morphology characterized
by noticeable fibrosis with the extracellular matrix collagen
contents and damage of liver cells structure (Fig. 7B and C).A
C
E
Figure 7 (A–F) Photomicrographs of liver sections in each group. (
omega 3 plus TAA (100 and 200) and (F) omega 3 (200) treated
Please cite this article in press as: Al-Attar, A.M., Al-Rethea, H.A. Chemoprotective
rats. Saudi Journal of Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.201Liver sections from omega-3 plus TAA treated rats showed a
reduced extent and development of fibrosis processes
(Fig. 7D and E). Moreover, the liver cells showed slight alter-
ations compared with liver cells structure of rats subjected to
only TAA.
Liver sections from rats treated with only TAA for six
weeks revealed an obvious increase in extracellular matrix col-
lagen content and bridging fibrosis. Furthermore, there were
bundles of collagen surrounding the lobules that resulted in
large fibrous septa and distorted tissue architecture. Liver sec-
tions from TAA treated rats showed an evidence of severe
histopathological alterations comprising nodular transforma-
tions in liver parenchyma similar to those found in human
nodular fibrosis. Moreover, the parenchyma nodules were sur-
rounded by the extension of fibrous septae which divided the
liver into pseudolobules. Additionally, the administration of
TAA caused centrilobular necrosis, hepatic cells surrounding
central vein showed various degenerative changes like cloudy
swelling, hydropic degeneration and necrosis with loss of
nucleus (Fig. 8A–C). Liver sections from omega-3 plus TAA
treated rats (Fig. 8D and E) showed improvements and reduc-
tion in fibrosis processes compared with liver sections of ratsB
D
F
A) Control (200), (B and C) TAA (100 and 200), (D and E)
rats for three weeks.
eﬀect of omega-3 fatty acids on thioacetamide induced hepatic ﬁbrosis in male
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Figure 8 (A–F) Photomicrographs of liver sections in treated groups. (A–C) TAA (100, 200 and 200), (D and E) omega 3 plus
TAA (100 and 200) and (F) omega 3 (200) treated rats for six weeks.
Chemoprotective effect of omega-3 fatty acids 7treated with only TAA. Moreover, the liver cells showed slight
alterations compared with liver cells’ structure of rats treated
with only TAA. Additionally, there are no any obvious fea-
tures of hepatic fibrosis in rats treated with omega-3 plus
TAA. Moreover, in omega 3 treated rats all sections of liver
tissue had normal structure (Fig. 8F).
4. Discussion
Liver fibrosis is a characteristic of most types of chronic liver
diseases. Liver fibrosis is a public health problem that results
in significant morbidity and mortality (Sa´nchez-Valle et al.,
2012). Liver fibrosis is a dynamic and highly integrated molec-
ular, tissue cellular process that drives the progression of
chronic liver diseases toward liver cirrhosis and hepatic failure
(Ezhilarasan et al., 2014). Moreover, liver fibrosis occurs as a
consequence of dynamic wound-healing response to acute or
chronic hepatocellular damage(s), and it poses a high threat
with significant morbidity and mortality (Hamza, 2010). The
field of hepatic fibrosis is flourishing thanks to continued
experimental advances complemented by exciting progress in
the treatment of chronic liver disease (Friedman et al., 2007).
Additionally, no acceptable therapeutic strategies exist. TherePlease cite this article in press as: Al-Attar, A.M., Al-Rethea, H.A. Chemoprotective
rats. Saudi Journal of Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.201is a huge need and great significance to search for effective
ways to inhibit liver fibrosis and prevent the development of
cirrhosis (Zou et al., 2008). Conventional, drugs used in the
treatment of liver diseases are sometimes inadequate and can
have serious adverse effects. Therefore, it is necessary to search
for alternative drugs for the treatment of liver disease in order
to replace currently used drugs of doubtful efficacy and safety
(Ozbek et al., 2004). In the absence of reliable liver protective
drugs in allopathic medical practices, natural products, herbs
and dietary antioxidants play a role in the management of var-
ious liver disorders (Bjelakovic et al., 2011; Buraimoh et al.,
2011). Therefore, it is very important and prudent to seek
for new sources for a safe and effective treatment of liver
diseases.
Physiologically, it is known that TAA toxicity is generally
associated with hepatic fibrosis induction, complicated meta-
bolic disorders and health problems (Al-Attar and Shawush,
2014). The present results showed that the maximum increases
in body weight were observed in control rats. The significant
increase in body weight in the control rats may be representa-
tive of the normal pattern of growth in rodents. On the con-
trary, the minimum increases in body weight were noted in
TAA treated rats accompanied with a notable increase ineﬀect of omega-3 fatty acids on thioacetamide induced hepatic ﬁbrosis in male
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8 A.M. Al-Attar, H.A. Al-Rethealiver/body ratio. These observations were also noted by other
studies (Wong et al., 2012; Kadir et al., 2013; Kabiri et al.,
2014; Zargar, 2014; Al-Attar and Shawush, 2015; Al-Attar
et al., 2015)
An increase in body weight implies that anabolic effects
have overridden the catabolic ones. No variation means pro-
tection against weight loss. A decrease in body weight would
mean that catabolism has persisted. The body weight decrease
as a result of TAA injection was considered to be the result of
direct toxicity of TAA and/or indirect toxicity related to the
liver damage. Moreover, the relative decrease in mean body
weight gain recorded in TAA treated rats may be adduced to
malnutrition resulting from reduced absorption of nutrients
from the intestine of treated rats. Furthermore, reduced adi-
pose tissue and proteins may be the foremost cause of lower
body weight. Additionally, the observed decrease in body
weight could be due to the direct effect of TAA on the food
intake behavior of the rats. TAA might have increased the pro-
tein catabolism and hampered the utilization of food con-
sumed during the intoxication period, thereby causing a
decrease in body weight. Such a reduction in body weight in
TAA-treated rats might be in part due to gastrointestinal tox-
icity and concomitant loss of the animal appetite with subse-
quent reduction of food ingestion or due to excessive loss of
water, salts and proteins as a result of renal injury with subse-
quent dehydration and weight loss.
Measurement of liver body weight ratio is a more accurate
approach to determine the changes in liver size compared to
the measurement of liver weight alone as the liver weight lar-
gely depends on the size of the rat. The enlargement of livers
in TAA treated rats signified hepatic lesions and liver injury
associated with the toxicological effects of TAA. Studies that
relate to liver weight change are complex (Rizzo et al., 1997).
Many factors are involved in the pathogenesis of this interac-
tion, including control of feeding behavior, fat storage mecha-
nisms, regulation of energy intake and energy expenditure, as
well as hormonal, genetic and psychological influences
(Lissner, 1993). When the liver is damaged, it can initiate
regenerative actions (Yamada and Fausto, 1998), thus increas-
ing the weight of liver. If it was heavily damaged, however,
liver fibrosis and cirrhosis appear resulting in liver atrophy
(Perez Tamayo, 1983). Therefore, the change in weight of liver
cannot directly predict the pathological process in chronic liver
injuries (Lin and Lin, 2006).
The present study showed that the administration of TAA
for three and six weeks induced an elevation in the levels of
serum ALT, AST, ALP, GGT and total bilirubin in rats, since
necrosis or membrane damage releases these enzymes into cir-
culation, which agrees with the previously reported results
(Kew, 2000). Moreover, many investigations showed that these
parameters were significantly enhanced in experimental ani-
mals exposed to TAA (Al-Attar, 2011, 2012; Ali et al., 2014;
Kim et al., 2014; Zargar, 2014; Abdou et al., 2015; Al-Attar
and Shawush, 2015; Al-Attar et al., 2015; Luo et al., 2015).
Damage of hepatocytes is reflected by an elevation in the levels
of hepato specific enzymes (ALT, AST, and ALP), these are
cytoplasmic in lection and are released into circulation after
cellular damage (Sallie et al., 1991). The increase in serum total
bilirubin may be owing to blockage of bile ductules as the
inflammation and fibrosis in the portal triads and/or due to
the regurgitation of conjugated bilirubin from the necrotic
hepatocytes to sinusoids (Ahmed, 2001). Additionally, ALT,Please cite this article in press as: Al-Attar, A.M., Al-Rethea, H.A. Chemoprotective
rats. Saudi Journal of Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.201AST, ALP and total bilirubin will leak into the serum resulting
in the elevation of their serum concentrations. Serum levels of
these parameters are very sensitive markers employed in the
diagnosis of liver diseases (de David et al., 2011).
Histopathological evaluations of the present study demon-
strated that severe alterations of liver structure were observed
in rats subjected to only TAA. However, the impact of TAA
depends on several factors such as its concentration, number
of doses, administration period, administration methods, ani-
mal’s gender, strain, age, weight and physiological case.
TAA is a toxin widely used for fibrosis-induction. It damages
both zone 1 and 3 hepatocytes with periportal injury being
more prominent than with other toxins. It is repeatedly
injected intraperitoneally or administered in the drinking water
(at a concentration adapted to water consumption). A long
time is needed for significant fibrosis (Salguero et al., 2008),
but this model is non invasive and requires minimal handling
of the animals. Cholangiocarcinoma and hepatocellular carci-
noma have been described in rats after a long time exposure to
TAA (Newell et al., 2008). The choice of the fibrosis-inducing
stimulus in an animal model is based on the expectation that
the response will engage mechanisms that are similar to those
occurring in the related human disease. In this study, TAA
induced severe hepatic damage as shown in histopathological
examination which coupled with markedly elevated levels of
liver hematobiochemical markers (ALT, AST, ALP, GGT
and total bilirubin).
The present study showed that the treatment with omega-3
fatty acids attenuated the physiological and histopathological
alterations induced by TAA in rats. This indicated the effec-
tiveness of omega-3 fatty acids in prevention of TAA toxicity.
The possible mechanism of the studied omega-3 fatty acids as
hepatoprotective factor may be due to its antioxidant effect
which impairs the activation of TAA into the reactive form.
Bruck et al. (2004) stated that the chronic of TAA administra-
tion induced liver cirrhosis and oxidative stress. Cruz et al.
(2005) reported that TAA induced liver fibrosis, oxidative
stress with extensive tissue damage and enhanced alpha-
smooth muscle actin expression in rat liver. Al-Attar (2012)
reported that the levels of liver superoxide dismutase (SOD)
and glutathione (GSH) were significantly decreased in mice
treated with TAA. Luo et al. (2015) reported that the level
of liver malondialdehyde (MDA) was significantly elevated
in TAA-treated rats while contents of SOD and GSH were
decreased compared with the control rats. Furthermore,
Mansour et al. (2015) showed that TAA induced hepatic
oxidative damage as indicated by an increase in lipid peroxida-
tion, a decrease in GSH and SOD activity as well as the
increased nitric oxide levels in experimental rats.
Atakisi et al. (2013) studied the effect of omega-3 fatty acids
on diethylnitrosamine (DEN) toxicity in rats. They suggested
that omega-3 fatty acids could ameliorate the toxic effects of
DEN in part by means of its free radical scavenging activity
and may be of therapeutic value in the protection of liver
against toxic effects of DEN. Kajikawa et al. (2011) assessed
the therapeutic effect of EPA and its mechanisms in an animal
model of nonalcoholic steatohepatitis (NASH). They con-
cluded that EPA attenuates the progression of hepatic fibrosis
in developed steatohepatitis, and this effect is likely mediated
by the inhibition of reactive oxygen species (ROS) production.
Alaraj and Qiblawi (2015) evaluated the role of fish oil in mod-
ulating carbon tetrachloride (CCl4) induced hepatotoxicity ineﬀect of omega-3 fatty acids on thioacetamide induced hepatic ﬁbrosis in male
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induced hepatocellular damage as evident from a significant
reduction in the elevated serum ALT, AST and bilirubin com-
pared to rabbits treated with CCl4 only. They concluded that
fish oil has a protective activity against CCl4 induced hepato-
toxicity and it can be proposed that fish oil can serve as a
potent hepatoprotective agent. Hassanen and Ahmed (2015)
investigated the hepatoprotective effect of fish oil against hep-
atotoxicity of DEN in rats. Significant increments in the activ-
ities of serum SOD, catalase (CAT), glutathione peroxidase
(GSPx) and GSH were observed in rats treated with DEN and
fish oil, while the level ofMDAwas significantly decreased. Fur-
thermore, treatment with fish oil reduces the histopathological
liver abnormalities associated with hepatotoxicity. Moreover
to the anti hepatotoxicity effect and possess antioxidant poten-
tial thatmay be used for therapeutic purposes suggested. Collec-
tively, the present study provided evidence indicating that
omega-3 fatty acids significantly exert noticeable biological
and pharmacological effects. From the present study, it is obvi-
ously that the pretreatment of rats with omega-3 fatty acids
attenuated the highly physiological and histopathological alter-
ations induced by TAA intoxication. Moreover, the present
results justify the development of additional physiological,
pharmacological and biochemical investigations in order to
clarify the exact mechanism of action of omega-3 fatty acids
against the effect of TAA. Finally, further experimental studies
are needed to pursue the influence of different doses of omega-3
fatty acid on hepatic fibrosis induced by TAA.
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